WO2022162012A3 - Anticorps ciblant sur un large spectre des coronavirus et leurs utilisations - Google Patents

Anticorps ciblant sur un large spectre des coronavirus et leurs utilisations Download PDF

Info

Publication number
WO2022162012A3
WO2022162012A3 PCT/EP2022/051776 EP2022051776W WO2022162012A3 WO 2022162012 A3 WO2022162012 A3 WO 2022162012A3 EP 2022051776 W EP2022051776 W EP 2022051776W WO 2022162012 A3 WO2022162012 A3 WO 2022162012A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
coronaviruses
relates
protein
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2022/051776
Other languages
English (en)
Other versions
WO2022162012A2 (fr
Inventor
Federica SALLUSTO
Antonio Lanzavecchia
Antonino Cassotta
Jun Siong LOW
Josipa JERAK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eidgenoessische Technische Hochschule Zurich ETHZ
Institute for Research in Biomedicine IRB
Original Assignee
Eidgenoessische Technische Hochschule Zurich ETHZ
Institute for Research in Biomedicine IRB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2021/051745 external-priority patent/WO2022161598A1/fr
Application filed by Eidgenoessische Technische Hochschule Zurich ETHZ, Institute for Research in Biomedicine IRB filed Critical Eidgenoessische Technische Hochschule Zurich ETHZ
Publication of WO2022162012A2 publication Critical patent/WO2022162012A2/fr
Publication of WO2022162012A3 publication Critical patent/WO2022162012A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des anticorps et des fragments de liaison à l'antigène de ceux-ci, qui se lient à la protéine de spicule (S) des coronavirus. Les anticorps, et des fragments de liaison à l'antigène de ceux-ci, ciblent sur un large spectre des coronavirus, comprenant différents alpha-et bêta-coronavirus. L'invention concerne également des acides nucléiques qui codent pour de tels anticorps et fragments d'anticorps et des cellules qui expriment de tels anticorps et fragments d'anticorps. De plus, l'invention concerne l'utilisation des anticorps et des fragments d'anticorps dans le traitement et le diagnostic d'une infection à coronavirus. En outre, l'invention concerne un peptide, un polypeptide ou une protéine de recombinaison comprenant l'épitope, auquel les anticorps se lient, et pouvant être utile dans la vaccination.
PCT/EP2022/051776 2021-01-26 2022-01-26 Anticorps ciblant sur un large spectre des coronavirus et leurs utilisations Ceased WO2022162012A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2021/051745 WO2022161598A1 (fr) 2021-01-26 2021-01-26 Anticorps ciblant largement des coronavirus et leurs utilisations
EPPCT/EP2021/051745 2021-01-26
EP2021078062 2021-10-11
EPPCT/EP2021/078062 2021-10-11

Publications (2)

Publication Number Publication Date
WO2022162012A2 WO2022162012A2 (fr) 2022-08-04
WO2022162012A3 true WO2022162012A3 (fr) 2022-09-09

Family

ID=80222205

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/051776 Ceased WO2022162012A2 (fr) 2021-01-26 2022-01-26 Anticorps ciblant sur un large spectre des coronavirus et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2022162012A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118440186A (zh) * 2023-01-05 2024-08-06 郴州市第一人民医院 一种广谱抗SARS-like冠状病毒和/或新冠突变株的抗体及其应用
CN118852420B (zh) * 2024-08-16 2025-11-11 东北农业大学 一种猪δ冠状病毒中和性单克隆抗体及其应用
CN119592517B (zh) * 2024-10-08 2025-09-19 河南农业大学 一种抗猪δ冠状病毒S2亚基的单克隆抗体及其杂交瘤细胞株和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100355470B1 (ko) 1993-11-17 2003-02-17 도이체 오엠 아르 쯔나이미텔 게엠바하 글루코사민이당류,그의제조방법,이를함유하는제약학적조성물,및그의용도
WO1999064301A1 (fr) 1998-06-08 1999-12-16 Sca Emballage France Emballage a remise a plat rapide
AU761396B2 (en) 1998-06-30 2003-06-05 Om Pharma Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
EP1597280B2 (fr) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Production d'anticorps monoclonaux par transformation de lymphocytes b par le virus d'epstein barr
US20090252729A1 (en) 2007-05-14 2009-10-08 Farrington Graham K Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto
NZ592036A (en) 2008-10-22 2012-12-21 Inst Research In Biomedicine Methods for producing antibodies from plasma cells
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALSAADI ENTEDAR A. J. ET AL: "A Fusion Peptide in the Spike Protein of MERS Coronavirus", VIRUSES, vol. 11, no. 9, 5 September 2019 (2019-09-05), pages 825, XP055917114, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784214/pdf/viruses-11-00825.pdf> [retrieved on 20220502], DOI: 10.3390/v11090825 *
CHEK MENG POH ET AL: "Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients", NATURE COMMUNICATIONS, vol. 11, no. 1, 1 June 2020 (2020-06-01), XP055746936, DOI: 10.1038/s41467-020-16638-2 *
DUAN J ET AL: "A human SARS-CoV neutralizing antibody against epitope on S2 protein", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 333, no. 1, 22 July 2005 (2005-07-22), pages 186 - 193, XP027218787, ISSN: 0006-291X, [retrieved on 20050623], DOI: 10.1016/J.BBRC.2005.05.089 *
JONES BRYAN E. ET AL: "Title: LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection", BIORXIV, 9 October 2020 (2020-10-09), XP055806789, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.09.30.318972v3.full.pdf> [retrieved on 20210523], DOI: 10.1101/2020.09.30.318972 *
LADNER JASON T. ET AL: "Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses", vol. 2, no. 1, 1 January 2021 (2021-01-01), pages 100189, XP055847640, ISSN: 2666-3791, Retrieved from the Internet <URL:https://www.cell.com/cell-reports-medicine/pdfExtended/S2666-3791(20)30244-5> [retrieved on 20211013], DOI: 10.1016/j.xcrm.2020.100189 *
PINTO DORA ET AL: "Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 583, no. 7815, 18 May 2020 (2020-05-18), pages 290 - 295, XP037289888, ISSN: 0028-0836, [retrieved on 20200518], DOI: 10.1038/S41586-020-2349-Y *
WANG CHUNYAN ET AL: "Isolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein", BIORXIV, 20 October 2020 (2020-10-20), pages 1 - 40, XP055916872, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.10.20.346916v1.full.pdf> [retrieved on 20220502], DOI: 10.1101/2020.10.20.346916 *
WEC ANNA Z. ET AL: "Broad neutralization of SARS-related viruses by human monoclonal antibodies", SCIENCE, vol. 369, no. 6504, 15 June 2020 (2020-06-15), US, pages 731 - 736, XP055845076, ISSN: 0036-8075, DOI: 10.1126/science.abc7424 *
ZHENG ZHIQIANG ET AL: "Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARSCoV-2", vol. 25, no. 28, 16 July 2020 (2020-07-16), FR, pages 1560 - 7917, XP055850940, ISSN: 1560-7917, Retrieved from the Internet <URL:https://www.eurosurveillance.org/deliver/fulltext/eurosurveillance/25/28/eurosurv-25-28-4.pdf?itemId=/content/10.2807/1560-7917.ES.2020.25.28.2000291&mimeType=pdf&containerItemId=content/eurosurveillance> [retrieved on 20211013], DOI: 10.2807/1560-7917.ES.2020.25.28.2000291 *

Also Published As

Publication number Publication date
WO2022162012A2 (fr) 2022-08-04

Similar Documents

Publication Publication Date Title
WO2022162012A3 (fr) Anticorps ciblant sur un large spectre des coronavirus et leurs utilisations
PH12021550793A1 (en) Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
MX2022013894A (es) Anticuerpos neutralizantes que se unen a la proteina s del sars-cov-2.
CY1121377T1 (el) Θεραπευτικα εμβολια hpv16
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
BR0213565A (pt) Anticorpo de anti-tnf alfa modificado
MX2023009244A (es) Anticuerpos contra la proteina espicular de coronavirus.
WO2023094713A3 (fr) Vaccin contre le coronavirus
MX2022012021A (es) Peptidos de dominios knob autonomos.
MX2023012902A (es) Proteinas de union a antigenos que se unen especificamente a prame.
MX2023007067A (es) Proteinas recombinantes de union a cd3 y su uso.
MX2020009550A (es) Proteinas de union a antigeno antagonistas.
BRPI0607097A2 (pt) peptìdeos de papiloma vìrus l2 n-terminais para a indução de anticorpos de neutralização amplamente cruzada
WO2025010376A3 (fr) Acides nucléiques, vecteurs et cellules codant pour des anticorps anti-sp17 et autres protéines de liaison sp17
WO2021050857A8 (fr) Anticorps anti-cd371 et leurs utilisations
WO2022067269A3 (fr) Anticorps contre le sars-cov-2
NZ591918A (en) Antibodies to modified human igf-1/e peptides
WO2023150724A3 (fr) Protéines de liaison à l&#39;antigène qui se lient à b7-h3
WO2024020590A3 (fr) Molécules de liaison à l&#39;antigène ciblant la lymphopoïétine stromale thymique (tslp)
WO2023196658A3 (fr) Compositions d&#39;anticorps et méthodes d&#39;optimisation
WO2022159839A8 (fr) Anticorps monoclonaux contre les coronavirus et leurs utilisations
MX2025010274A (es) Composiciones para su uso en el tratamiento de clamidia
MX2025004782A (es) Anticuerpos de dominio individual que se unen a la neurotoxina del tetanos
WO2023141176A3 (fr) Anticorps neutralisants et fragments de liaison à l&#39;antigène de ceux-ci contre omicron et d&#39;autres variants de coronavirus, et leurs méthodes de fabrication et d&#39;utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22702920

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22702920

Country of ref document: EP

Kind code of ref document: A2